Gregory J. Divis - 09 Nov 2026 Form 4 Insider Report for InMed Pharmaceuticals Inc. (MTRI)

SEC form
4
Accepted by SEC
12 Nov 2026, 16:30:27 UTC
Prior SEC filing
12 Nov 2026
Source filing
View source filing
Filing notes and source

Key filing fact

Gregory J. Divis filed Form 4 for InMed Pharmaceuticals Inc. (MTRI) on 12 Nov 2026.

Key facts

  • This page summarizes Gregory J. Divis's Form 4 filing for InMed Pharmaceuticals Inc. (MTRI).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 12 Nov 2026, 16:30.

Change

  • Previous filing in this sequence was filed on 12 Nov 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001410677 Primary reporting owner

Divis Gregory J

Relationship
President and Chief Executive Officer, Director

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MTRI transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares
+1,560,599
Change %
Price
$0.000000*
Shares after
1,560,599
Date
09 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,560,599
Exercise price
$16.00
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option represents the right to purchase 1,560,599 shares of the Issuer's common stock and will vest as to 25% on November 9, 2027 and in equal monthly installments thereafter through November 9, 2030, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

SEC remarks

President and Chief Executive Officer

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .